Rivaroxaban (Xarelto) Discontinuation Before EGD
For a diagnostic EGD (low-risk procedure), omit only the morning dose of rivaroxaban on the day of the procedure. For a therapeutic EGD with interventions like polypectomy or variceal treatment (high-risk procedure), stop rivaroxaban 3 days (72 hours) before the procedure. 1
Risk Stratification is Critical
The duration of rivaroxaban discontinuation depends entirely on whether your EGD is low-risk or high-risk:
Low-Risk EGD Procedures
- Diagnostic upper endoscopy with or without biopsy
- Management: Simply skip the morning dose on the day of the procedure 1
- This minimal interruption maintains anticoagulation protection while allowing safe endoscopy
High-Risk EGD Procedures
- Therapeutic interventions: polypectomy, endoscopic mucosal resection, variceal band ligation, laser therapy, mucosal ablation, or any intervention with significant bleeding risk 1, 2
- Management: Last dose should be taken 3 days (72 hours) before the procedure 1
The Evidence Behind This Recommendation
The 2021 BSG/ESGE guidelines provide the most authoritative and recent guidance on this topic 1. These recommendations are supported by the PAUSE trial, which demonstrated that standardized interruption protocols (2 days for low-risk, 3 days for high-risk procedures) resulted in low rates of both major bleeding and thromboembolism 1.
Key pharmacokinetic rationale: Rivaroxaban has a relatively short half-life and reaches full anticoagulant activity within 3 hours of dosing. The 3-day interruption for high-risk procedures allows approximately 5 half-lives to elapse, ensuring minimal residual anticoagulant effect 1. Research confirms that 95% of patients will have rivaroxaban concentrations ≤30 ng/ml after 48 hours of discontinuation, which is considered hemostatically safe 3.
Special Consideration: Renal Function
If you have impaired renal function, different rules apply—but this primarily affects dabigatran, not rivaroxaban. The standard 3-day interruption for rivaroxaban applies regardless of renal function for most patients 1. However, if renal function is rapidly deteriorating, consult hematology 1.
Resumption of Therapy
- Low-risk procedures: Resume rivaroxaban the same day or next day after the procedure
- High-risk procedures: Resume 2-3 days after the procedure, once hemostasis is secure 1
Common Pitfalls to Avoid
Don't confuse rivaroxaban with dabigatran: Dabigatran requires longer interruption (5 days) in patients with reduced creatinine clearance, but rivaroxaban does not 1
Don't routinely bridge with heparin: Unlike warfarin management, bridging anticoagulation is NOT recommended for DOAC interruption in most cases 1
Don't rely on INR or aPTT: These tests are unreliable for monitoring rivaroxaban activity 1
Assess thrombotic risk: If the patient has very high thrombotic risk (recent stroke, mechanical heart valve, recent VTE), discuss the management plan with their cardiologist or hematologist before proceeding 1